SLC35B2 and melanoma: To confirm that Vemurafenib-treated YAP5SA melanoma cells rely on SLC35B2, we generated two monoclonal cell populations with CRISPR/Cas9-mediated knockout of SLC35B2 in SKMEL28-YAP5SA (abbreviated as SLC35B2-S1 and SLC35B2-S2) and A375-YAP5SA (abbreviated as SLC35B2-A1 and SLC35B2-A2) cells, respectively.